The National Institute of Diabetes and Digestive and Kidney Diseases at the NIH awarded the Kansas PKD Center a five-year grant (U54) that provides funding to support our innovative biomedical research cores.
PI: James Calvet, PhD
The mission of the Kansas PKD Research and Translation Core Center (RTCC) is to promote PKD research by providing essential reagents, biomaterials, and service to the PKD research community for the advancement of our understanding of disease mechanisms, the discovery of biomarkers and therapeutic targets and the development of clinical trials to improve patient outcomes. The mission of the Center is based on research at Kansas that discovered and characterized many of the key pathways now being considered for PKD therapy, and that ultimately led to the development of Tolvaptan as the first FDA-approved therapy for ADPKD. The Kansas PKD RTCC has created three biomedical research cores to support the research programs of external core users in the PKD Research Consortium and the greater PKD research community.
These cores are:
Core 1: Biomarkers, Biomaterials, and Cellular Models (Darren Wallace, Ph.D., Director)
Core 2: Rodent Models & Drug Testing (Pamela Tran, Ph.D. and Stephen Parnell, Ph.D., Co-Directors)
Core 3: Clinical Research (Alan Yu, M.B., B.Chir, Director)